Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: VLV011
MIFTS: 52

Vulvovaginal Candidiasis

Categories: Infectious diseases, Reproductive diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Vulvovaginal Candidiasis

About this section

MalaCards integrated aliases for Vulvovaginal Candidiasis:

Name: Vulvovaginal Candidiasis 12 15 17 3
Candidiasis, Vulvovaginal 45 74
Candidiasis of Vulva and Vagina 12
Candidiasis Vulvovaginal 56
Candidal Vulvovaginitis 12
Monilial Vulvovaginitis 12

Classifications:

MalaCards categories:
Global: Infectious diseases
Anatomical: Reproductive diseases
See all MalaCards categories (disease lists)
ICD10: 34


External Ids:

Disease Ontology 12 DOID:2272
ICD9CM 36 112.1
MeSH 45 D002181
NCIt 51 C2914
SNOMED-CT 69 72605008
ICD10 34 B37.3
UMLS 74 C0700345
Sources

Summaries for Vulvovaginal Candidiasis

About this section
CDC : 3 Candidiasis is an infection caused by a yeast (a type of fungus) called Candida. Candida normally lives inside the body (in places such as the mouth, throat, gut, and vagina) and on skin without causing any problems. Sometimes Candida can multiply and cause an infection if the environment inside the vagina changes in a way that encourages its growth. Candidiasis in the vagina is commonly called a “vaginal yeast infection.” Other names for this infection are “vaginal candidiasis,” “vulvovaginal candidiasis,” or “candidal vaginitis.”

MalaCards based summary : Vulvovaginal Candidiasis, also known as candidiasis, vulvovaginal, is related to candidiasis and bacterial vaginosis. An important gene associated with Vulvovaginal Candidiasis is MBL2 (Mannose Binding Lectin 2), and among its related pathways/superpathways are IL-2 Pathway and Toll-like Receptor Signaling Pathway. The drugs Clindamycin and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and colon, and related phenotypes are hematopoietic system and homeostasis/metabolism

Disease Ontology : 12 A candidiasis that involves fungal infection of the vaginal mucous membranes in women caused by Candida albicans. The symptoms include intense vulval pruritus, burning, erythema and dyspareunia associated with a creamy white, curd-like discharge.

Wikipedia : 77 Vaginal yeast infection, also known as candidal vulvovaginitis and vaginal thrush, is excessive growth... more...

Sources

Related Diseases for Vulvovaginal Candidiasis

About this section

Diseases related to Vulvovaginal Candidiasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 160)
# Related Disease Score Top Affiliating Genes
1 candidiasis 31.6 CLEC7A DEFB4A IFNG MBL2
2 bacterial vaginosis 31.0 DEFB4A MBL2 TLR2
3 vulvar vestibulitis syndrome 30.5 MBL2 NLRP3
4 coccidioidomycosis 10.4 CLEC7A MBL2
5 candida glabrata 10.4
6 immunoglobulin g deficiency 10.4 CD79A MBL2
7 immunoglobulin alpha deficiency 10.3 CD79A MBL2
8 trichomoniasis 10.3
9 corneal abscess 10.3 DEFB1 DEFB4A
10 osteonecrosis of the jaw 10.3 DEFB1 DEFB4A
11 prosthetic joint infection 10.3 MBL2 TLR2
12 diabetes mellitus 10.3
13 vulvovaginitis 10.3
14 cervicitis 10.2 DEFB4A IL2
15 fungal keratitis 10.2 CLEC7A TLR2
16 haemophilus influenzae 10.2 CLEC7A TLR2
17 tularemia 10.2 MBL2 TLR2
18 neisseria meningitidis infection 10.2 MBL2 TLR2
19 mycobacterium kansasii 10.2 NLRP3 TLR2
20 oral candidiasis 10.2 DEFB1 DEFB4A
21 congenital hypogammaglobulinemia 10.2 CD79A IL4
22 immunodeficiency with hyper-igm, type 1 10.2 CD79A IL4
23 chromoblastomycosis 10.2 CLEC7A IL4
24 localized scleroderma 10.2 DEFB1 DEFB4A
25 septic arthritis 10.1 DEFB4A TLR2
26 virus associated hemophagocytic syndrome 10.1 IL2 IL4
27 autoimmune vasculitis 10.1 IL2 IL4
28 jak3-deficient severe combined immunodeficiency 10.1 IL2 IL4
29 allergic bronchopulmonary aspergillosis 10.1 IL4 MBL2
30 angiostrongyliasis 10.1 IL2 IL4
31 sebaceous gland disease 10.1 CD79A DEFB4A TLR2
32 gaucher disease, type ii 10.1 IL2 IL4
33 sporotrichosis 10.1 CD79A IFNG
34 wells syndrome 10.1 IL2 NLRP3
35 autoimmune gastritis 10.1 IL2 IL4
36 milk allergy 10.1 CD79A IL4
37 chronic graft versus host disease 10.1 CD79A IFNG
38 strongyloidiasis 10.1 CD79A IFNG
39 microscopic colitis 10.0 CD79A IFNG
40 mycobacterium abscessus 10.0 CLEC7A NLRP3 TLR2
41 neurofibromatosis, type ii 10.0 DEFB1 DEFB4A TLR2
42 conjunctival disease 10.0 IL4 NLRP3
43 filarial elephantiasis 10.0 IL4 TLR2
44 multiple sclerosis 10.0
45 cystic fibrosis 10.0
46 human immunodeficiency virus type 1 10.0
47 deficiency anemia 10.0
48 iron deficiency anemia 10.0
49 iron metabolism disease 10.0
50 human immunodeficiency virus infectious disease 10.0

Comorbidity relations with Vulvovaginal Candidiasis via Phenotypic Disease Network (PDN): (show all 12)


Acute Cystitis Anxiety
Bronchitis Decubitus Ulcer
Deficiency Anemia Esophagitis
Heart Disease Hypertension, Essential
Hypothyroidism Oral Candidiasis
Osteoporosis Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Vulvovaginal Candidiasis:



Diseases related to Vulvovaginal Candidiasis
Sources

Symptoms & Phenotypes for Vulvovaginal Candidiasis

About this section

MGI Mouse Phenotypes related to Vulvovaginal Candidiasis:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.97 CD101 CD79A CLEC7A IFNG IL2 IL4
2 homeostasis/metabolism MP:0005376 9.86 CD79A CLEC7A IFNG IL2 IL4 MBL2
3 digestive/alimentary MP:0005381 9.85 CLEC7A IFNG IL2 IL4 NLRP3 TLR2
4 immune system MP:0005387 9.81 CD101 CD79A CLEC7A IFNG IL2 IL4
5 liver/biliary system MP:0005370 9.43 CD79A IFNG IL2 IL4 NLRP3 TLR2
6 renal/urinary system MP:0005367 9.1 CD79A IFNG IL4 MBL2 NLRP3 TLR2
Sources

Drugs & Therapeutics for Vulvovaginal Candidiasis

About this section

Drugs for Vulvovaginal Candidiasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 84)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clindamycin Approved, Vet_approved Phase 4,Phase 3,Early Phase 1,Not Applicable 18323-44-9 29029
2
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 22916-47-8 4189
3
Clotrimazole Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 23593-75-1 2812
4
Fluconazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 86386-73-4 3365
5
Dequalinium Approved, Investigational Phase 4 6707-58-0
6
Terconazole Approved Phase 4,Phase 3,Not Applicable,Early Phase 1 67915-31-5 441383
7
Metronidazole Approved Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable 443-48-1 4173
8
Tinidazole Approved, Investigational Phase 4,Phase 3 19387-91-8 5479
9
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
10 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
11 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable
12 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
13 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
14 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
15 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
16 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
17 Antibiotics, Antitubercular Phase 4,Phase 3,Not Applicable
18 Antitubercular Agents Phase 4,Phase 3
19 Clindamycin palmitate Phase 4,Phase 3,Early Phase 1,Not Applicable
20 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
21 Clindamycin phosphate Phase 4,Phase 3,Early Phase 1,Not Applicable
22 Cytochrome P-450 CYP2C9 Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
23 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
24 Cytochrome P-450 CYP2C19 Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
25 Anti-Infective Agents, Local Phase 4,Phase 3
26 Immune Sera Phase 4
27 Immunologic Factors Phase 4,Phase 3,Phase 1,Phase 2
28
Tetracycline Approved, Vet_approved Phase 3 60-54-8 5353990
29
Ketoconazole Approved, Investigational Phase 3 65277-42-1 47576
30
Amphotericin B Approved, Investigational Phase 3,Phase 2 1397-89-3 14956 5280965
31
Azithromycin Approved Phase 3 83905-01-5 55185 447043
32
Rifabutin Approved, Investigational Phase 3 72559-06-9 6323490 46783538
33
leucovorin Approved Phase 3 58-05-9 6006 143
34
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
35
Secnidazole Approved Phase 3 3366-95-8
36
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
37 Antiprotozoal Agents Phase 3,Phase 2,Early Phase 1,Not Applicable
38 Antiparasitic Agents Phase 3,Phase 2,Early Phase 1,Not Applicable
39 Liposomal amphotericin B Phase 3,Phase 2
40 Alkylating Agents Phase 3
41 Dermatologic Agents Phase 3
42 Antirheumatic Agents Phase 3
43 Folic Acid Antagonists Phase 3
44 Antimetabolites, Antineoplastic Phase 3
45 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
46 Vitamin B9 Phase 3
47 Folate Phase 3
48 Antimetabolites Phase 3
49 Vitamin B Complex Phase 3
50 Immunosuppressive Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 68)
# Name Status NCT ID Phase Drugs
1 Use of Boric Acid in Combination With Probiotics for the Treatment of Vaginal Infections Unknown status NCT02860845 Phase 4 Antibiotic (Clindamycin);Antifungal (Clotrimazole)
2 Comparative Efficacy Study of 10 mg Dequalinium Chloride (Fluomizin) in the Treatment of Vulvovaginal Candidiasis Completed NCT02242695 Phase 4 Fluomizin vaginal tablets;Canesten vaginal tablets
3 Epidemiological Study About the Evolution of Patients Treated for an Acute Episode of Vulvovaginal Candidiasis Completed NCT02248506 Phase 4
4 Terconazole Vaginal Suppository vs Fluconazole for the Treatment of Severe Vulvovaginal Candidiasis Completed NCT02180100 Phase 4 Terconazole Vaginal Suppository;Fluconazole
5 Clotrimazole Vaginal Tablet vs Fluconazole for Severe Vulvovaginal Candidiasis Completed NCT02180828 Phase 4 Clotrimazole vaginal tablet;Fluconazole
6 Effect of Exercise on Spread of the Miconozole Nitrate OVULE in the Vagina Completed NCT00194324 Phase 4 Miconazole nitrate
7 Lactoserum (Dermacyd Femina®) and Prevention of Recurrence of Bacterial Vaginosis Completed NCT00556179 Phase 4 Lactoserum (Dermacyd Femina®)
8 Evaluation of Efficacy and Safety of Gynomax® XL Ovule Not yet recruiting NCT03839875 Phase 4 Gynomax® XL Vaginal Ovule
9 The Study Of Fluconazole For Vulvovaginal Candidiasis Completed NCT01806623 Phase 3 Fluconazole
10 Diabetes Mellitus and Vulvovaginal Candidiasis Completed NCT00353561 Phase 3 Boric;Fluconazole
11 ProF-001_Phase IIa Completed NCT03115073 Phase 2, Phase 3 Candiplus;Clotrimazole
12 Study of the Efficacy and Tolerance of Intra-vaginal Treatment With a Total Freeze-dried Culture of Lcr Regenerans® in the Prevention of Relapses of Recurrent Vulvovaginal Candidiasis Completed NCT02251093 Phase 3 Lcr Regenerans;Placebo
13 A Study to Compare the Efficacy and Safety of a Combination of Ketoconazole and Clindamycin Compared to Tetracycline/Amphotericin B Combination Cream for the Treatment of Bacterial Vaginosis and Vaginal Candidiasis (P08077) Completed NCT01293643 Phase 3 100 mg clindamycin /800 mg ketoconazole vaginal ovule;100 mg tetracycline hydrochloride /50 mg amphotericin B cream
14 Comparative Efficacy of Ovule vs Tablet Completed NCT00755053 Phase 3 Clotrimazole, vaginal ovule;Clotrimazole, vaginal tablet
15 A Randomized Study of Daily and Intermittent Prophylactic Regimens for the Prevention of Disseminated Mycobacterium Avium Complex (MAC) and Fungal Infections in HIV-Infected Patients Completed NCT00002122 Phase 3 Azithromycin;Rifabutin;Fluconazole
16 Study of the Management of Vaginal Discharge in West African Using Single Dose Treatments Completed NCT00313131 Phase 3 tinidazole+fluconazole vs metronidazole+clotrimazole
17 A Study to Evaluate Efficacy of Tocilizumab Administered as Monotherapy or in Combination With Methotrexate and/or Other Disease Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis (RA) Participants Completed NCT01941940 Phase 3 Tocilizumab;DMARDs
18 Safety and Clinical and Microbiological Efficacy of the Combination of Fluconazole and Secnidazole for the Treatment of Symptomatic Vaginal Discharge Completed NCT02111629 Phase 3 Fluconazole and Secnidazole
19 A Study of Oral VT-1161 for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection) Recruiting NCT03562156 Phase 3 VT-1161;Placebo
20 A Study of Oral VT-1161 for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection) Recruiting NCT03561701 Phase 3 VT-1161;Placebo
21 Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis Recruiting NCT03734991 Phase 3 Ibrexafungerp;Placebo
22 Treatment of Candidal Vulvovaginitis Using Cumin Seed Extract Vaginal Cream. Recruiting NCT03005353 Phase 2, Phase 3 Cumin seed extract;clotrimazole
23 Ketoconazole Gel Versus Terconazole Cream for Vaginal Candidiasis Not yet recruiting NCT03473418 Phase 3 Ketoconazole;Terconazole
24 A Study of Oral VT-1161 for the Treatment of Acute Vaginal Candidiasis (Yeast Infection) in Patients With Recurrent Vaginal Candidiasis Not yet recruiting NCT03840616 Phase 3 VT-1161 150 mg capsule;Fluconazole 150 mg
25 Efficacy, Safety LactiSal 1% Gel, LactSal 50 mg, Clotrimazole 100 mg Tablet in Treatment Vulvovaginal Candidiasis Withdrawn NCT02907307 Phase 3 Clotrimazole vaginal tablet 100mg
26 A Study to Evaluate Oral VT-1161 in the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection) Completed NCT02267382 Phase 2 VT-1161;Placebo
27 Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis Completed NCT01926028 Phase 1, Phase 2
28 MGCD290 and Fluconazole Versus Fluconazole Alone for the Treatment of Moderate to Severe Vulvovaginal Candidiasis Completed NCT01497223 Phase 2 MGCD290
29 Safety and Efficacy of Oral SCY-078 vs. Oral Fluconazole in Subjects With Vulvovaginal Candidiasis Completed NCT02679456 Phase 2 SCY-078;Fluconazole
30 An Active-Controlled, Dose-Finding Study of SCY-078 vs. Oral Fluconazole in Subjects With Acute Vulvovaginal Candidiasis Completed NCT03253094 Phase 2 Fluconazole;SCY-078
31 Arasertaconazole Nitrate Pessaries - Dose Finding Study for the Vulvovaginal Candidiasis (VVC) Treatment Completed NCT01144286 Phase 2 arasertaconazole nitrate;placebo
32 A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Acute Vaginal Candidiasis (Yeast Infection) Completed NCT01891331 Phase 2 VT-1161;Fluconazole
33 Safety and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) in the Treatment of Vulvovaginal Candidiasis (VVC) Completed NCT02971007 Phase 2 Oral Encochleated Amphotericin B (CAMB);Fluconazole
34 Topical Metronidazole and Miconazole Co-formulated Vaginal Suppositories for Preventing Vaginal Infections in HIV-seronegative Women Completed NCT01230814 Phase 2 Neo-Penotran® Forte (active ingredient Metronidazole & Miconazole Nitrate);Placebo
35 RADIANT: CD101 vs Standard of Care in Subjects With Acute Vaginal Yeast Infections Completed NCT02733432 Phase 2 CD101 Vaginal Gel (3%);CD101 External gel (1%);CD101 Vaginal Ointment (6%);CD101 External ointment (1%);Fluconazole
36 TOL-463 Phase 2 Study for Vaginitis Completed NCT02866227 Phase 2 TOL-463;TOL-463
37 Safety and Efficacy Study of Lactobacillus Administered Vaginally in Women With Bacterial Vaginosis Completed NCT00635622 Phase 2 LACTIN-V;Placebo control substance
38 Patients With Vulvovaginal Candidiasis Recruiting NCT03024502 Phase 1, Phase 2 EPP-AF Gel 1%;EPP-AF Gel 2%;Clotrimazole
39 Dose-finding Study of GSK2248761 in Antiretroviral Therapy-experienced Subjects With NNRTI-resistant HIV Infection Terminated NCT01199731 Phase 2 GSK2248761 100 mg once daily;GSK2248761 200 mg once daily;Etravirine
40 Efficacy and Safety of Oral Encochleated Amphotericin B (CAMB) in the Treatment of Fluconazole-Resistant Vulvovaginal Candidiasis Withdrawn NCT03167957 Phase 2 Oral Encochleated Amphotericin B (CAMB);Oral Encochleated Amphotericin B (CAMB)
41 Use of Oral Probiotics as an Adjunctive Therapy to Fluconazole in the Treatment of Yeast Vaginitis Unknown status NCT00479947 Phase 1 Probiotics (Natural product);Probiotics (L. rhamnosus GR-1 and L. reuteri RC-14)
42 Safety and Immunogenicity Study of a Virosomal Vaccine Against Recurrent Vulvovaginal Candida Infection Completed NCT01067131 Phase 1
43 Evaluation of Intravaginal Gel and Ovule Formulations of TOL-463 Completed NCT01812889 Phase 1 TOL-463 Vaginal ovule;TOL-463 Vaginal gel
44 Study Evaluating the Optimal Dosage for Equivalence Between Lcr Regenerans® Capsules and Tablets (Lactobacillus Rhamnosus Lcr35®) on the Vaginal Flora Colonisation Completed NCT02730494 Phase 1
45 Use of 405nm Blue Light Emitting Diode in the Treatment of Women With Vulvovaginal Candidiasis: a Clinical Trial Unknown status NCT03075046 Not Applicable
46 Will Vaginal Colonization of Lactobacillus Increase Cure Rate After Treatment of Bacterial Vaginosis and Chronic Vulvovaginal Candida Unknown status NCT02295579
47 Diagnosing Bacterial Vaginosis/Vaginitis (BV) Using the Gynecologene Test Method Unknown status NCT02558179
48 Safety and Equivalence of a Terconazole Vaginal Suppository (Test Product) Compared to the Reference Terconazole Vaginal Suppository in the Treatment of Vulvovaginal Candidiasis Completed NCT00803738 Not Applicable Terconazole Vaginal Suppository;Terazol Vaginal Suppository
49 Monthly Itraconazole Versus Classic Homeopathy for Treatment of Recurrent Vulvovaginal Candidiasis (RVVC) Completed NCT00895453 Not Applicable itraconazole;lactobacillus gasseri;classic homeopathy (carcinosin M, nux vomica, pulsatilla M, ferrum metallicum, sepia M, etc. as prescribed)
50 A Randomized Study Evaluating the Therapeutic Equivalence of Two Butoconazole Nitrate Vaginal Cream, 2% Formulations Completed NCT01039584 Not Applicable Butoconazole Nitrate Vaginal Cream;Placebo;Gynazole 1 vaginal cream

Search NIH Clinical Center for Vulvovaginal Candidiasis

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: candidiasis, vulvovaginal

Sources

Genetic Tests for Vulvovaginal Candidiasis

About this section
Sources

Anatomical Context for Vulvovaginal Candidiasis

About this section

MalaCards organs/tissues related to Vulvovaginal Candidiasis:

42
Skin, Testes, Colon, Neutrophil, B Cells
Sources

Publications for Vulvovaginal Candidiasis

About this section

Articles related to Vulvovaginal Candidiasis:

(show top 50) (show all 460)
# Title Authors Year
1
Vulvovaginal candidiasis: histologic lesions are primarily polymicrobial and invasive and do not contain biofilms. ( 30595144 )
2019
2
Enhanced antifungal activity of bovine lactoferrin-producing probiotic Lactobacillus casei in the murine model of vulvovaginal candidiasis. ( 30621597 )
2019
3
Impaired Th17 cell proliferation and decreased pro-inflammatory cytokine production in CXCR3/CXCR4 double-deficient mice of vulvovaginal candidiasis. ( 30656691 )
2019
4
Comparing the effectiveness of Salvia officinalis, clotrimazole and their combination on vulvovaginal candidiasis: A randomized, controlled clinical trial. ( 30663184 )
2019
5
Intravaginal Delivery of Syngonanthus nitens (Bong.) Ruhland Fraction Based on a Nanoemulsion System Applied to Vulvovaginal Candidiasis Treatment. ( 30890237 )
2019
6
CD101 Topical Compared With Oral Fluconazole for Acute Vulvovaginal Candidiasis: A Randomized Controlled Trial. ( 30893271 )
2019
7
The changes of antifungal susceptibilities caused by the phenotypic switching of Candida species in 229 patients with vulvovaginal candidiasis. ( 30101450 )
2019
8
Long-Term Outcomes of Women With Recurrent Vulvovaginal Candidiasis After a Course of Maintenance Antifungal Therapy. ( 29975334 )
2018
9
New evidence on oral L. plantarum P17630 product in women with history of recurrent vulvovaginal candidiasis (RVVC): a randomized double-blind placebo-controlled study. ( 29364495 )
2018
10
Risk Factors of Vulvovaginal Candidiasis among Women of Reproductive Age in Xi'an: A Cross-Sectional Study. ( 29977925 )
2018
11
Risk of major congenital malformations following first-trimester exposure to vaginal azoles used for treating vulvovaginal candidiasis: a population-based retrospective cohort study. ( 29790255 )
2018
12
A phase 2, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate theA efficacy and safety of orally administeredA VT-1161 inA the treatment of recurrentA vulvovaginal candidiasis. ( 29534874 )
2018
13
Pulsatilla decoction inhibits Candida albicans proliferation and adhesion in a mouse model of vulvovaginal candidiasis via the Dectin-1 signaling pathway. ( 29775695 )
2018
14
Human Anti-Als3p Antibodies Are Surrogate Markers of NDV-3A Vaccine Efficacy Against Recurrent Vulvovaginal Candidiasis. ( 29963049 )
2018
15
Surface-modified mucoadhesive microgels as a controlled release system for miconazole nitrate to improve localized treatment of vulvovaginal candidiasis. ( 28986195 )
2018
16
Novel Mechanism behind the Immunopathogenesis of Vulvovaginal Candidiasis: "Neutrophil Anergy". ( 29203543 )
2018
17
Antifungal susceptibilities, in vitro production of virulence factors and activities of ceragenins against Candida spp. isolated from vulvovaginal candidiasis. ( 29846682 )
2018
18
The effect of a vaginal suppository formulation of dill (Anethum graveolens) in comparison to clotrimazole vaginal tablet on the treatment of vulvovaginal candidiasis. ( 29553834 )
2018
19
Nanolipid Gel of an Antimycotic Drug for Treating Vulvovaginal Candidiasis-Development and Evaluation. ( 29340981 )
2018
20
Vulvovaginal candidiasis: species distribution of Candida and their antifungal susceptibility pattern. ( 29902998 )
2018
21
Thymol, eugenol and lactobacilli in a medical device for the treatment of bacterial vaginosis and vulvovaginal candidiasis. ( 29874389 )
2018
22
Amphotericin B-Loaded Plga Nanofibers: an Alternative Therapy Scheme for Local Treatment of Vulvovaginal Candidiasis. ( 29940181 )
2018
23
Antimicrobial photodynamic therapy as a new approach for the treatment of vulvovaginal candidiasis: preliminary results. ( 29931589 )
2018
24
Current treatment options for vulvovaginal candidiasis caused by azole-resistant Candida species. ( 29932786 )
2018
25
RISK FACTORS OF VULVOVAGINAL CANDIDIASIS IN DERMATO-VENEREOLOGY OUTPATIENTS CLINIC OF SOETOMO GENERAL HOSPITAL, SURABAYA, INDONESIA. ( 29619437 )
2018
26
Longitudinal trajectory of vulvovaginal candidiasis, trichomoniasis, and bacterial vaginosis during pregnancy as well as the impact on pregnancy outcomes: a preliminary study. ( 29685081 )
2018
27
A Therapeutic Vaccine for Recurrent Vulvovaginal Candidiasis. ( 29697770 )
2018
28
A Fungal Immunotherapeutic Vaccine (NDV-3A) for Treatment of Recurrent Vulvovaginal Candidiasis-A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial. ( 29697768 )
2018
29
Computer-aided diagnosis software for vulvovaginal candidiasis detection from Pap smear images. ( 28987021 )
2018
30
Development, characterization, and in vitro-in vivo evaluation of polymeric nanoparticles containing miconazole and farnesol for treatment of vulvovaginal candidiasis. ( 29361177 )
2018
31
Mannose-Binding Lectin Gene Polymorphism and Its Association with Susceptibility to Recurrent Vulvovaginal Candidiasis. ( 29850562 )
2018
32
Formulation, stability study, and pre-clinical evaluation of a vaginal cream containing curcumin in a rat model of vulvovaginal candidiasis. ( 29517833 )
2018
33
Safety and Efficacy of a Novel Vaginal Anti-infective, TOL-463, in the Treatment of Bacterial Vaginosis and Vulvovaginal Candidiasis: A Randomized, Single-blind, Phase 2, Controlled Trial. ( 30184181 )
2018
34
Randomised clinical trial in women with Recurrent Vulvovaginal Candidiasis: Efficacy of probiotics and lactoferrin as maintenance treatment. ( 30565745 )
2018
35
Contribution of TLR2 pathway in the pathogenesis of vulvovaginal candidiasis. ( 30052917 )
2018
36
Epitope unmasking in vulvovaginal candidiasis is associated with hyphal growth and neutrophilic infiltration. ( 30063729 )
2018
37
Vulvovaginal candidiasis in reproductive age women in Enugu Nigeria, clinical versus laboratory-assisted diagnosis. ( 30074004 )
2018
38
Global burden of recurrent vulvovaginal candidiasis: a systematic review. ( 30078662 )
2018
39
Vaginal lipidomics of women with vulvovaginal candidiasis and cytolytic vaginosis: A non-targeted LC-MS pilot study. ( 30133508 )
2018
40
The Relationship Between Vulvovaginal Candidiasis and Provoked Vulvodynia: A Systematic Review. ( 30145093 )
2018
41
Curcumin-Loaded Liquid Crystalline Systems for Controlled Drug Release and Improved Treatment of Vulvovaginal Candidiasis. ( 30184431 )
2018
42
Prevalence of vulvovaginal candidiasis in gynecological practices in Germany: A retrospective study of 954,186 patients. ( 30186987 )
2018
43
Candida africana in recurrent vulvovaginal candidiasis (RVVC) patients: frequency and phenotypic and genotypic characteristics. ( 30248002 )
2018
44
Alternative and complementary therapies for vulvovaginal candidiasis. ( 30269301 )
2018
45
Natural products for vulvovaginal candidiasis treatment: evidence from clinical trials. ( 30277156 )
2018
46
Inhibition of CXCR4 by MicroRNA-1192 Reduces the Activation of Th17 Cells and Expression of Inflammation Factors in a Mouse Model of Vulvovaginal Candidiasis. ( 30355939 )
2018
47
Nystatin enhances the immune response against Candida albicans and protects the ultrastructure of the vaginal epithelium in a rat model of vulvovaginal candidiasis. ( 30359236 )
2018
48
Efficacy of antifungal drugs in the treatment of vulvovaginal candidiasis: a Bayesian network meta-analysis. ( 30425538 )
2018
49
Biofilms and vulvovaginal candidiasis. ( 30447520 )
2018
50
In vivo applicability of Neosartorya fischeri antifungal protein 2 (NFAP2) in treatment of vulvovaginal candidiasis. ( 30478163 )
2018
Sources

Variations for Vulvovaginal Candidiasis

About this section
Sources

Expression for Vulvovaginal Candidiasis

About this section
Search GEO for disease gene expression data for Vulvovaginal Candidiasis.
Sources

Pathways for Vulvovaginal Candidiasis

About this section

Pathways related to Vulvovaginal Candidiasis according to GeneCards Suite gene sharing:

(show all 31)
# Super pathways Score Top Affiliating Genes
1
IL-2 Pathway 65
Show member pathways
 13.01 CD79A IFNG IL2 IL4 TLR2
2
Toll-like Receptor Signaling Pathway 38 1
Show member pathways
 12.98 IFNG IL2 MBL2 NLRP3 TLR2
3
Innate Immune System 67
Show member pathways
 12.96 CD101 CD79A CLEC7A DEFB1 DEFB4A IFNG
4
Immune response NFAT in immune response 23
Show member pathways
 12.44 CD79A IFNG IL2 IL4
5
Th17 cell differentiation 38
Show member pathways
 12.41 IFNG IL2 IL4 TLR2
6
Influenza A 38
Show member pathways
 12.37 IFNG IL2 IL4 NLRP3 TLR2
7
Defensins 67
Show member pathways
 12.18 DEFB1 DEFB4A TLR2
8
NF-kappaB Signaling 4
12.17 CD79A IFNG IL2 IL4 TLR2
9
Selenium Micronutrient Network 1
Show member pathways
 12.16 IFNG IL2 IL4
10
IL-17 Family Signaling Pathways 66
Show member pathways
 12.14 DEFB4A IFNG IL4 TLR2
11
Toxoplasmosis 38
Show member pathways
 12.08 IFNG IL4 TLR2
12
Tuberculosis 38
12.06 CLEC7A IFNG TLR2
13
C-type lectin receptor signaling pathway 38
Show member pathways
 12.03 CLEC7A IL2 NLRP3
14
Bacterial infections in CF airways 23
Show member pathways
 11.98 DEFB4A IFNG IL4 TLR2
15
Phagosome 38
11.97 CLEC7A MBL2 TLR2
16
Th1 Differentiation Pathway 66
Show member pathways
 11.9 IFNG IL2 TLR2
17
Microglia Activation During Neuroinflammation: Overview 66
Show member pathways
 11.87 IFNG IL4 TLR2
18
Spinal Cord Injury 1
11.85 IFNG IL2 IL4
19
IL12-mediated signaling events 1
Show member pathways
 11.81 IFNG IL2 IL4
20
Glucocorticoid receptor regulatory network 1
11.64 IFNG IL2 IL4
21
Calcineurin-regulated NFAT-dependent transcription in lymphocytes 1
Show member pathways
 11.59 IFNG IL2 IL4
22
Microglia Activation During Neuroinflammation: Microglia Polarization 66
11.55 IFNG IL2 IL4
23
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 66
11.52 CD79A IFNG IL2 IL4
24
Th2 Differentiation Pathway 66
11.32 IFNG IL2 IL4
25
Innate Lymphoid Cell Differentiation Pathways 66
11.16 CD101 IFNG IL2 IL4
26
Development and heterogeneity of the ILC family 1
11.15 IFNG IL4
27
Inflammatory Response Pathway 1
11.13 IFNG IL2 IL4
28
IL12 signaling mediated by STAT4 1
11.08 IFNG IL2
29
Cytokines and Inflammatory Response 1
11.04 IFNG IL2 IL4
30
OX40 Pathway 65
10.96 IFNG IL2 IL4
31
IL1 and megakaryocytes in obesity 1
10.9 IFNG NLRP3 TLR2
Sources

GO Terms for Vulvovaginal Candidiasis

About this section

Cellular components related to Vulvovaginal Candidiasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.43 DEFB1 DEFB4A IFNG IL2 IL4 MBL2
2 extracellular region GO:0005576 9.17 DEFB1 DEFB4A IFNG IL2 IL4 MBL2

Biological processes related to Vulvovaginal Candidiasis according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 innate immune response GO:0045087 9.72 CLEC7A DEFB1 MBL2 NLRP3 TLR2
2 defense response GO:0006952 9.65 DEFB1 DEFB4A NLRP3
3 immune system process GO:0002376 9.63 CD79A CLEC7A IL2 MBL2 NLRP3 TLR2
4 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.54 IFNG IL2 IL4
5 B cell activation GO:0042113 9.52 CD79A IL4
6 positive regulation of interleukin-12 production GO:0032735 9.51 IFNG TLR2
7 positive regulation of T cell differentiation GO:0045582 9.49 IL2 IL4
8 regulation of regulatory T cell differentiation GO:0045589 9.46 IFNG IL2
9 positive regulation of isotype switching to IgG isotypes GO:0048304 9.43 IL2 IL4
10 immune response GO:0006955 9.43 DEFB1 DEFB4A IFNG IL2 IL4 TLR2
11 positive regulation of interleukin-13 production GO:0032736 9.4 IL4 NLRP3
12 cytokine secretion involved in immune response GO:0002374 9.26 NLRP3 TLR2
13 defense response to Gram-positive bacterium GO:0050830 9.02 DEFB1 DEFB4A MBL2 NLRP3 TLR2

Molecular functions related to Vulvovaginal Candidiasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 carbohydrate binding GO:0030246 9.5 CLEC7A IL2 MBL2
2 cytokine activity GO:0005125 9.43 IFNG IL2 IL4
3 peptidoglycan binding GO:0042834 9.16 NLRP3 TLR2
4 signaling pattern recognition receptor activity GO:0008329 8.96 CLEC7A TLR2
5 CCR6 chemokine receptor binding GO:0031731 8.62 DEFB1 DEFB4A
Sources

Sources for Vulvovaginal Candidiasis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....